Jim Cramer is Recommending These Stocks
Jim Cramer in a recent program talked about the importance of The Dow Jones Industrial Average touching the 40,000 mark for the first time ever. Cramer said that the Dow hitting its new highs was a "t...
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
| 5.06 | |
| 5.18 | |
| - | |
| 5.24 | |
| 4.96 | |
| 3.49-7.6 | |
| 327 M | |
| 64 307 K | |
| 11 380 K | |
| -0.32 | |
| 1.338 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Jim Cramer in a recent program talked about the importance of The Dow Jones Industrial Average touching the 40,000 mark for the first time ever. Cramer said that the Dow hitting its new highs was a "t...
Shares of MeiraGTx Holdings PLC (MGTX) have gained 53.4% over the past four weeks to close the last trading session at $6.92, but there could still be a solid upside left in the stock if short-term pr...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: